These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16498049)

  • 1. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism.
    Mazziotti G; Amato G; Sorvillo F; Piscopo M; Rizzo MR; Lalli E; Iride L; Cioffi M; Molinari AM; Paolisso G; Carella C
    Eur J Endocrinol; 2006 Mar; 154(3):373-7. PubMed ID: 16498049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang Zh; Sun LH; Xu MY; Chen JL
    Calcif Tissue Int; 2005 Jan; 76(1):1-6. PubMed ID: 15455183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
    Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
    Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients.
    Mesquita M; Wittersheim E; Demulder A; Dratwa M; Bergmann P
    Adv Perit Dial; 2005; 21():181-4. PubMed ID: 16686314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
    Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
    Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.
    Granchi D; Pellacani A; Spina M; Cenni E; Savarino LM; Baldini N; Giunti A
    J Bone Joint Surg Am; 2006 Jul; 88(7):1501-9. PubMed ID: 16818976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
    Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
    Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in patients with neuroblastoma.
    Granchi D; Garaventa A; Amato I; Paolucci P; Baldini N
    Int J Cancer; 2006 Jul; 119(1):146-51. PubMed ID: 16450378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
    Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
    Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
    Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
    Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer.
    Jung K; Stephan C; Semjonow A; Lein M; Schnorr D; Loening SA
    J Urol; 2003 Dec; 170(6 Pt 1):2302-5. PubMed ID: 14634401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
    Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.
    Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E
    Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
    Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
    J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.
    Rogers A; Eastell R
    J Clin Endocrinol Metab; 2005 Nov; 90(11):6323-31. PubMed ID: 16105967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report].
    Minenna G; D'Amore S; Maggiolini P; Scagliusi P; D'Amore M
    Recenti Prog Med; 2005 Sep; 96(9):431-2. PubMed ID: 16229324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
    Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
    Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.